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lished head to head comparisons between all AAPs, response
rates were obtained from individual studies for each AAP. Total
annual costs were calculated based on 1.3 acute manic episodes
per year and included costs of AAPs, concurrent medications,
adverse events, and medical resource utilization. All costs were
inﬂated to 2005 values. Incremental cost-effectiveness and sen-
sitivity analyses will be conducted. RESULTS: The total annual
costs per patient were $7897, $7778, $7807, $7730, and $7829
for aripiprazole, ziprasidone, risperidone, quetiapine, and 
olanzapine, respectively. Given the response rates and costs per
patient listed above, the CE ratios were $17,356, $15,555,
$13,360, $14,504, and $13,807, respectively. CONCLUSIONS:
These ﬁndings suggest that, among AAPs, treatment with risperi-
done may be the most cost-effective choice for acute manage-
ment of mania in patients with bipolar I disorder. The results of
this model are limited to a 3-week acute treatment of mania, thus
no conclusions can be drawn about the cost-effectiveness of
AAPs when used as maintenance treatment.
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OBJECTIVES: To assess changes in cost and effectiveness para-
meters following switch from risperidone to olanzapine during
the long-term treatment of schizophrenia patients. METHODS:
Patients were participants in a randomized, open-label, 1-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted antipsychotic switching when clinically warranted.
Resource utilization was systematically abstracted from medical
records. Treatment outcomes were assessed with standard 
psychiatric measures. Statistical analyses assessed changes from
pre-to-post switch among patients who were randomized to
risperidone, but later switched to olanzapine for any cause.
RESULTS: Sixty of the 218 (27.5%) patients randomized to
risperidone switched antipsychotics—with 43 (72%) switching
to olanzapine. Average duration on risperidone before switching
to olanzapine was 86.1 days (mean maximum dose 4.5mg/day).
Most of these switchers (86%) completed the 1-year study on
olanzapine (average maximum dose 13.3mg/day). Following
switch to olanzapine, patients experienced signiﬁcant improve-
ments on clinical and social parameters (both, p < 0.001), with
35.7% of the prior non-remitters achieving remission status.
Mean total daily costs changed from $49.5/day pre-switch, to
$44.4/day post-switch (non-signiﬁcant difference). CONCLU-
SIONS: Olanzapine appears to be a cost effective “rescue”
option for patients who require switching from risperidone in
the long-term treatment of schizophrenia.
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OBJECTIVES: Chronic schizophrenia is a high prevalence
disease in Mexico which generates signiﬁcant disabilities and
economic expenditures on the Mexican Health System. The
purpose of the study was to model the economic consequences
of adverse events (AE) related with ﬁve antipsychotic drugs in
adult patients in the Social Security Mexican Institute.
METHODS: A cost–effectiveness model was developed using a
Markov modeling approach. The model simulated treatment of
a cohort of 1000 schizophrenics for twelve months, initiating
treatment with one of ﬁve antipsychotic drugs; haloperidol (10
mg), ziprasidone (80mg), risperidone (4mg), olanzapine (15mg)
and clozapine (300mg). Conditional probabilities of developing
any AE (akathisia, weight gain, extrapyramidal symptoms) were
obtained according to clinical trials previously published and
were adjusted with local expert opinion surveys. Treatment was
susceptible to be modiﬁed (decrease dose, switch medication).
Effectiveness measure was the number of free months of psy-
chotic symptoms. The analysis was conducted from the health-
care payer’s perspective (only direct medical costs were used).
Resource use and costs were obtained from hospital records of
the biggest psychiatric hospital in Mexico (“Hospital San 
Fernando”). Probabilistic sensitivity analysis was performed 
and acceptability curves were constructed. RESULTS: Zipra-
sidone showed the lower expected annual costs per patient
(US$17,159.5 ± 7,605.1) and the higher number of free months
of psychotic symptoms (9.2 ± 1.5 months). Ziprasidone was 
followed by risperidone and clozapine who obtained annual
expected costs of US$19,589.2 and US$24,656.1; and effective-
ness of 8.8 and 8.9 months, respectively. Results were robust to
Monte Carlo second order sensitivity analysis. Acceptability
curves showed the same results with a mean of 60% of certainty.
CONCLUSIONS: In Mexico, ziprasidone resulted the treatment
most cost–effective, followed by risperidone, clozapine and olan-
zapine. These results should be taken into account by Mexican
decision makers and clinicians in the management of patients
with chronic schizophrenia.
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OBJECTIVES: This study examined health care and resource 
utilization associated with atypical antipsychotic treatment for
bipolar disorder. METHODS: Using the NC Medicaid Claims
database 3328 patients were identiﬁed who had 3 months pre-
and 12 months post-treatment initiation data. Patients diagnosed
with bipolar disorder were classiﬁed into three groups based on
type of treatment during the ﬁrst 30 days after treatment initia-
tion (index date): atypical antipsychotic (AP2) monotherapy,
atypical antipsychotic plus mood stabilizer (AP2 + MS) combi-
nation therapy, and mood stabilizer (MS) monotherapy. For the
12 month treatment period, total bipolar-related and total
health-related costs were examined including and excluding
index medication. Comparative costs of index medications were
also analyzed. Propensity score matching was employed to
balance baseline characteristics between the three comparison
groups. Gamma regression models were further employed to 
estimate the average treatment effect on the cost outcomes.
RESULTS: Compared to MS monotherapy, AP2 monotherapy
and AP2 + MS therapy incurred higher index medication costs
during the treatment period. Patients on AP2 monotherapy
incurred signiﬁcantly lower total health-related costs excluding
index medication (-10.9%, p < 0.046), leading to no statistical
difference in total health-related cost including index medication
(1.5%, p < 0.76). In terms of total bipolar-related costs, patients
on AP2 monotherapy had higher costs than MS monotherapy
when including index medication costs (14.9%, p < 0.01).
However, bipolar-related costs excluding index medication cost
was signiﬁcantly lower (-16.7%, p < 0.03). Results were similar
